Akari Therapeutics Plc.
AKTX.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Akari Therapeutics, Plc is a biopharmaceutical company, which focuses on the development and commercialization of therapeutics to treat autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, which is a second-generation complement inhibitor that acts on complement component C...Show More
Better Health for All
20
Akari Therapeutics is a biopharmaceutical company focused on developing therapeutics for autoimmune, inflammatory diseases, and cancer. Its lead asset, nomacopan, targets diseases like pediatric HSCT-TMA, which has an 80% mortality rate, and geographic atrophy.
1
The company is also developing novel Antibody Drug Conjugates for cancer treatment.
2
The entire business is devoted to health improvement. The company has no revenue from products, thus no revenue from harmful products.
3
All research and development expenses, which were $9.6 million in 2022 and $0.8 million in Q1 2025, are aimed at improving health outcomes.
4
A composition of matter patent application was filed for long-acting PAS-nomacopan versions, with potential protection until 2042, and the company is securing IP for nomacopan in other pipeline programs.
5
Fair Money & Economic Opportunity
0
No evidence available to assess Akari Therapeutics Plc on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
No quantitative data is available to assess Akari Therapeutics Plc against the Fair Pay & Worker Respect ethical value. The company has an employee count of 1 to 50.
1
While the Interim President & CEO's compensation is noted as solely equity-based with no cash, severance, or performance bonuses, median employee compensation data is absent, preventing the calculation of a CEO-to-median-pay ratio.
2
No other specific, concrete data points regarding employee compensation, benefits, working conditions, or labor practices are provided in the available articles.
Fair Trade & Ethical Sourcing
0
No evidence available to assess Akari Therapeutics Plc on Fair Trade & Ethical Sourcing.
Honest & Fair Business
0
The provided articles indicate that Akari Therapeutics Plc has governance documents in place, including a Code of Business Conduct and Ethics, a Code of Ethics for Principal Executive Officer and Senior Financial Officer, a Whistleblower Policy, and an Insider Trading Policy, all dated between June 14 and June 19, 2023.
1
The company also resolved a Nasdaq Stock Market listing deficiency, returning to full compliance with listing requirements.
2
However, no specific quantitative data or details regarding the strength, enforcement, or outcomes related to any of the 'Honest & Fair Business' KPIs are provided in the articles, preventing any tier assignments.
Kind to Animals
-50
The company conducts animal studies and uses animal models in drug development and testing, including preclinical studies and xenograft models.
1
It has conducted toxicity studies in certain animals and intends to conduct further long-term animal toxicity studies, including reproductive and carcinogenicity studies.
2
The company has not disclosed a formal policy restricting or reducing animal testing.
3
While no specific volume of animals used is provided, the ongoing and planned nature of these studies indicates a routine use of animals in testing.
4
The company states it complies with Good Laboratory Practices (GLP), which are standards for conducting animal studies, but this does not constitute a policy to reduce or eliminate animal testing.
5
No War, No Weapons
0
No evidence available to assess Akari Therapeutics Plc on No War, No Weapons.
Planet-Friendly Business
0
The company's total Scope 1, 2, and 3 greenhouse gas emissions are 156 metric tons CO2e.
1
This is a very low figure, suggesting a non-material GHG emissions footprint. Water usage is 0 m³ per $1 M revenue, as the company reported $1.2 million in revenue in 2023 and 0 m³ of water usage.
2
Respect for Cultures & Communities
0
No evidence available to assess Akari Therapeutics Plc on Respect for Cultures & Communities.
Safe & Smart Tech
0
The company has not reported any specific data breaches or materially affecting cybersecurity incidents.
1
No incidents of unauthorized data use have been reported.
2
Users are stated to have rights to access, correct, delete, restrict, or object to the processing of their data, and to withdraw consent.
3
The company's policy is to keep data only as long as necessary and in accordance with local law.
4
It mentions compliance with applicable local law, and no specific regulatory actions, violations, or fines related to cybersecurity or privacy are noted.
5
Information regarding AI ethics, cybersecurity investment, privacy certifications, security training, encryption, authentication security, vulnerability management, bug bounty programs, privacy by design, security testing coverage, algorithmic harm remediation, or digital rights advocacy is not available.
Zero Waste & Sustainable Products
0
No sustainability data or specific information regarding waste management, product recyclability, packaging, or other zero waste and sustainable product initiatives for Akari Therapeutics Plc was found in the provided articles.
1
The articles explicitly state that no relevant data is available or that they only contain search results without detailed sustainability practices.
2